Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
77% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. OMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OMED' s Cash to Debt Range Over the Past 10 Years
Min: 290.2  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.02
OMED's Equity to Asset is ranked lower than
93% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OMED: 0.02 )
Ranked among companies with meaningful Equity to Asset only.
OMED' s Equity to Asset Range Over the Past 10 Years
Min: -1.81  Med: 0.02 Max: 0.35
Current: 0.02
-1.81
0.35
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
68% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -1.04
M-Score: 9.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -330.33
OMED's Operating margin (%) is ranked lower than
67% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. OMED: -330.33 )
Ranked among companies with meaningful Operating margin (%) only.
OMED' s Operating margin (%) Range Over the Past 10 Years
Min: -330.35  Med: -109.30 Max: -48.52
Current: -330.33
-330.35
-48.52
Net-margin (%) -329.75
OMED's Net-margin (%) is ranked lower than
68% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. OMED: -329.75 )
Ranked among companies with meaningful Net-margin (%) only.
OMED' s Net-margin (%) Range Over the Past 10 Years
Min: -329.77  Med: -108.26 Max: -47.87
Current: -329.75
-329.77
-47.87
ROE (%) -197.30
OMED's ROE (%) is ranked lower than
92% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. OMED: -197.30 )
Ranked among companies with meaningful ROE (%) only.
OMED' s ROE (%) Range Over the Past 10 Years
Min: -213.74  Med: -132.59 Max: -51.43
Current: -197.3
-213.74
-51.43
ROA (%) -38.53
OMED's ROA (%) is ranked lower than
62% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. OMED: -38.53 )
Ranked among companies with meaningful ROA (%) only.
OMED' s ROA (%) Range Over the Past 10 Years
Min: -35.17  Med: -23.78 Max: -12.61
Current: -38.53
-35.17
-12.61
ROC (Joel Greenblatt) (%) -914.12
OMED's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. OMED: -914.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1038.97  Med: -487.36 Max: -385.14
Current: -914.12
-1038.97
-385.14
Revenue Growth (3Y)(%) -67.60
OMED's Revenue Growth (3Y)(%) is ranked lower than
89% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OMED: -67.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMED' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -67.60 Max: -65.4
Current: -67.6
EBITDA Growth (3Y)(%) -49.30
OMED's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. OMED: -49.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMED' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -51.10 Max: -49.3
Current: -49.3
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

OMED Guru Trades in Q1 2015

Jim Simons Sold Out
PRIMECAP Management 206,293 sh (-5.54%)
» More
Q2 2015

OMED Guru Trades in Q2 2015

Jim Simons 24,942 sh (New)
PRIMECAP Management 190,800 sh (-7.51%)
» More
Q3 2015

OMED Guru Trades in Q3 2015

Jim Simons 67,700 sh (+171.43%)
PRIMECAP Management 190,800 sh (unchged)
» More
Q4 2015

OMED Guru Trades in Q4 2015

PRIMECAP Management 191,800 sh (+0.52%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 102.97
OMED's P/B is ranked lower than
98% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. OMED: 102.97 )
Ranked among companies with meaningful P/B only.
OMED' s P/B Range Over the Past 10 Years
Min: 3.52  Med: 9.25 Max: 191.02
Current: 102.97
3.52
191.02
P/S 14.04
OMED's P/S is ranked lower than
56% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. OMED: 14.04 )
Ranked among companies with meaningful P/S only.
OMED' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 11.20 Max: 26.09
Current: 14.04
1.02
26.09
Current Ratio 4.39
OMED's Current Ratio is ranked lower than
53% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OMED: 4.39 )
Ranked among companies with meaningful Current Ratio only.
OMED' s Current Ratio Range Over the Past 10 Years
Min: 3.55  Med: 5.14 Max: 6.25
Current: 4.39
3.55
6.25
Quick Ratio 4.39
OMED's Quick Ratio is ranked lower than
51% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. OMED: 4.39 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s Quick Ratio Range Over the Past 10 Years
Min: 3.55  Med: 5.14 Max: 6.25
Current: 4.39
3.55
6.25
Days Sales Outstanding 996.34
OMED's Days Sales Outstanding is ranked lower than
100% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. OMED: 996.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 62.71 Max: 996.38
Current: 996.34
0.22
996.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 103.42
OMED's Price/Tangible Book is ranked lower than
97% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. OMED: 103.42 )
Ranked among companies with meaningful Price/Tangible Book only.
OMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.35  Med: 8.51 Max: 191.02
Current: 103.42
7.35
191.02
Price/Median PS Value 1.28
OMED's Price/Median PS Value is ranked lower than
69% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. OMED: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
OMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.47 Max: 2.35
Current: 1.28
0.36
2.35
Earnings Yield (Greenblatt) (%) -40.60
OMED's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. OMED: -40.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -81.3  Med: 0.00 Max: 0
Current: -40.6
-81.3
0

More Statistics

Revenue(Mil) $26
EPS $ -2.84
Beta2.07
Short Percentage of Float7.02%
52-Week Range $8.42 - 26.72
Shares Outstanding(Mil)30.28

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -3.00
EPS without NRI($) -3.00

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5,... Apr 29 2016
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5,... Apr 29 2016
Big Pharma grooves $20 billion M&A dance with 2 Bay Area biotechs Apr 28 2016
AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion Apr 28 2016
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting Apr 21 2016
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting Apr 21 2016
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the... Apr 20 2016
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the... Apr 20 2016
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 Apr 19 2016
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 Apr 19 2016
OncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : April 4, 2016 Apr 04 2016
OncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US :... Apr 01 2016
ETF’s with exposure to OncoMed Pharmaceuticals, Inc. : March 29, 2016 Mar 29 2016
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and... Mar 17 2016
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016 Mar 16 2016
ONCOMED PHARMACEUTICALS INC Financials Mar 16 2016
ETF’s with exposure to OncoMed Pharmaceuticals, Inc. : March 15, 2016 Mar 15 2016
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
Edited Transcript of OMED earnings conference call or presentation 10-Mar-16 9:30pm GMT Mar 11 2016
OncoMed reports 4Q loss Mar 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK